Morphic Holding, Inc. (MORF)

Market Cap	1.57B
Revenue (ttm)	n/a
Net Income (ttm)	-161.25M
Shares Out	50.09M
EPS (ttm)	-3.50
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	312,113
Open	32.38
Previous Close	32.55
Day's Range	31.21 - 32.66
52-Week Range	19.35 - 62.08
Beta	1.48
Analysts	Buy
Price Target	54.40 (+73.91%)
Earnings Date	Aug 1, 2024

About MORF

Morphic Holding, Inc., a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, metabolic diseases, as well as fibrosis and cancer. Its lead product candidates are MORF-057, an a4ß7-specific integrin inhibitor affecting inflammation that is in Phase 1 clinical trial for the treatment of inflammatory bowel disease; and preclinical trial to treat idiopathic pulmonary fibrosis and fibrosis diseases. The company is also developing avß6 for the treatment of fibroti...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 27, 2019
• Employees: 121
• Stock Exchange: NASDAQ
• Ticker Symbol: MORF

Financial Performance

In 2023, MORF's revenue was $521,000, a decrease of -99.26% compared to the previous year's $70.81 million. Losses were -$152.10 million, 157.6% more than in 2022.

Analyst Forecast

According to 6 analysts, the average rating for MORF stock is "Buy." The 12-month stock price forecast is $54.4, which is an increase of 73.91% from the latest price.

Price Target

$54.4

(73.91% upside)

Analyst Consensus: Buy